Additional file 2 of Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results

Osuga, Yutaka, Seki, Yoshifumi, Tanimoto, Masataka, Kusumoto, Takeru, Kudou, Kentarou, Terakawa, Naoki
2021 · doi:10.6084/m9.figshare.14821129.v1 · W6939513779
article OA: green CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This study presents 24-week safety and efficacy results for relugolix, an oral GnRH receptor antagonist, in women with endometriosis-associated pain, detailing changes in pelvic pain, dysmenorrhea, and dyspareunia scores.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Additional file 2. Change from baseline in mean of M-B&B score for pelvic pain, dysmenorrhea, and dyspareunia by visit.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrheadyspareunia

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-13T18:33:16.088889+00:00
License: CC0 · commercial use OK